» Articles » PMID: 12702589

Overexpression of Vascular Endothelial Growth Factor Isoforms Drives Oxygenation and Growth but Not Progression to Glioblastoma Multiforme in a Human Model of Gliomagenesis

Overview
Journal Cancer Res
Specialty Oncology
Date 2003 Apr 19
PMID 12702589
Citations 12
Authors
Affiliations
Soon will be listed here.
Abstract

Vascular endothelial growth factor (VEGF) is thought to promote tumor growth and angiogenesis. Whereas VEGF is up-regulated in only a portion of anaplastic astrocytoma (AA), it is overexpressed in most glioblastoma multiforme (GBM), and the level of expression is correlated with grade of glioma. To explore the possibility that VEGF may act as a driving force in the progression of AA to GBM, the VEGF isoforms VEGF(121) and VEGF(165) were overexpressed in genetically modified, mutant H-Ras-transformed human astrocytes that on intracranial implantation form AA-like tumors. The ability of the VEGF isoforms to stimulate growth, angiogenesis, oxygenation, and the formation of necrotic GBM-like tumors was then monitored. The parental mutant H-Ras-modified astrocytes expressed four times more endogenous VEGF than normal human astrocytes, but on intracranial implantation formed hypovascular, hypoxic, small AA-like tumors. Whereas these modest levels of VEGF overexpression were insufficient to drive oxygenation and GBM formation, an additional 8-fold increase in VEGF expression mediated by retroviral infection with constructs encoding either VEGF (121) or VEGF (165) resulted in cells which, after intracranial implantation, formed tumors that were larger, more vascular, and better oxygenated than those formed by the mutant H-ras parental cells. However, the tumors formed by the cells expressing exogenous VEGF (121) or VEGF (165) retained the phenotype of AA, lacking areas of necrosis that are the hallmark of the GBM phenotype. These results suggest that whereas the VEGF(121) and VEGF(165) isoforms can contribute to glioma vascularization, oxygenation, and growth, they do not in and of themselves drive the formation of the GBM phenotype.

Citing Articles

Research progress of anti-glioma chemotherapeutic drugs (Review).

Zhou Y, Wang W, Chen N, Wang L, Huang J Oncol Rep. 2022; 47(5).

PMID: 35362540 PMC: 8990335. DOI: 10.3892/or.2022.8312.


Evaluation of VEGF, FGF and PDGF and Serum Levels of Inflammatory Cytokines in Patients with Glioma and Meningioma in Southern Iran.

Shamsdin S, Mehrafshan A, Rakei S, Mehrabani D Asian Pac J Cancer Prev. 2019; 20(10):2883-2890.

PMID: 31653130 PMC: 6982662. DOI: 10.31557/APJCP.2019.20.10.2883.


Effects of Far-infrared Ray on Temozolomide-treated Glioma in Rats.

Chen J, Hwang J In Vivo. 2019; 33(4):1203-1208.

PMID: 31280210 PMC: 6689335. DOI: 10.21873/invivo.11591.


Neurovascular patterning cues and implications for central and peripheral neurological disease.

Gamboa N, Taussky P, Park M, Couldwell W, Mahan M, Kalani M Surg Neurol Int. 2017; 8:208.

PMID: 28966815 PMC: 5609400. DOI: 10.4103/sni.sni_475_16.


Mutant IDH1 Expression Drives TERT Promoter Reactivation as Part of the Cellular Transformation Process.

Ohba S, Mukherjee J, Johannessen T, Mancini A, Chow T, Wood M Cancer Res. 2016; 76(22):6680-6689.

PMID: 27758882 PMC: 5290072. DOI: 10.1158/0008-5472.CAN-16-0696.